- Country or region
- Trade topics
- Exporters' stories
- EU exporter
Grindeks’ product portfolio is composed of original products, generics and active pharmaceutical ingredients, all produced in line with global requirements of safety and quality.
- Founded in: 1946
- Headquarters: Riga, Latvia
- Employees: 1,486
- turnover: EUR 187 million (in 2020)
- Joint Stock Company “Grindeks”
Grindeks is an international pharmaceutical group, and its main activities are research, development, production and sale of original products, generics and active pharmaceutical ingredients.
Grindeks’ main therapeutic groups are cardiovascular, central nervous system, anti-cancer and diabetes medicines. Subsidiary company Kalceks specialises in medicines for the hospital segment. The product range consists of the original products Mildronate® and Ftorafur®, generics, as well as active pharmaceutical ingredients.
Grindeks’ major markets are the European Union countries, Russia and other CIS countries, Israel, Canada and the USA.
How the EU-Canada trade agreement helps
CETA broke down trade barriers, and ensured a more transparent and stable trading environment. Also, the reduction of tariffs made us more competitive in the market.
Grindeks Group continues its development and growth with confidence, achieving historically high profit and turnover.
“We are looking forward to using all instruments to help our business expand to new markets. Our high quality products and cooperation with global partners offer a high growth potential for Grindeks inside the EU and all across the globe.”